In vivo Evaluation of C. difficile Enoyl-ACP Reductase II (FabK) Inhibition by Phenylimidazole Unveils a Promising Narrow-Spectrum Strategy for CDI Therapeutics
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP455650
下载链接
链接失效反馈官方服务：
资源简介：
FabK is the sole ENR reductase in C. difficile. Fecal microbiota investigation of Mus musculus on the treatment with vancomycin, fidaxomicin, and phenylimidazole analog 296 was done with the purpose of confirming it to be a promising narrow-spectrum therapeutic target to particularly inhibit C. difficile.
创建时间：
2023-09-16
